Search clinical trials for: Guanfacine Hydrocholride

Total 7167 results

Shire

Completed

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Attention-Deficit/Hyperactivity Disorder

United States, Canada
Maastricht University Medical Center
Shire

Completed

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity (SPD503-315)

Attention Deficit Disorder

Netherlands
Rochester Center for Behavioral Medicine
Shire

Completed

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). (ADINT2012)

Adult Attention-Deficit Hyperactivity Disorder

United States
Shire

Completed

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

ADHD

United States
Shire

Completed

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention-deficit/Hyperactivity Disorder

Spain, Belgium, United States, Netherlands, United Kingdom, Italy, Germany, Canada, France, Sweden
Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, United States, United Kingdom, Belgium, Germany, Netherlands, Portugal, Austria, Sweden
Shire

Completed

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

Attention-Deficit/Hyperactivity Disorder

United States
Rachel G. Greenberg, MD, MB, MHS
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Not yet recruiting

Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) (HYP01)

Hyperactivity in Children With Down Syndrome | Impulsivity in Children With Down Syndrome

United States
Shire

Completed

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, United States, Germany, Poland, Italy, Ukraine, Romania, United Kingdom, Sweden, Austria, Canada, France, Ireland
Shire

Completed

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Phobia, Social | Anxiety, Separation | Generalized Anxiety Disorder (GAD)

United States
Icahn School of Medicine at Mount Sinai

Completed

Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD

ADHD | Attention Deficit Hyperactivity Disorder

United States
Shire

Completed

Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

Attention Deficit Disorder With Hyperactivity
Shire

Completed

Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

Attention Deficit Disorder With Hyperactivity
Children's Specialized Hospital
Shire

Terminated

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Insomnia | Sleep Disorders | Attention-Deficit/Hyperactivity Disorder | Attention Deficit Disorder

United States
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Does Guanfacine Attenuate Stress-Induced Drinking?

Alcohol Drinking

United States
Stony Brook University

Recruiting

Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)

Alcohol Abstinence

United States
National Center for Research Resources (NCRR)
Yale University

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder

Tourette Syndrome
US Department of Veterans Affairs

Completed

Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)

Post-Traumatic Stress Disorder

United States
Shire

Completed

Guanfacine Immediate-release Electrocardiogram Results (QTc) Study

Healthy Volunteers

United States
Shire

Completed

Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

Attention Deficit Disorder With Hyperactivity
Neurology Group of Bergen County, P.A.
Shire

Completed

Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine

Attention-deficit/Hyperactivity Disorder

United States
Orygen
University of Melbourne; Youth Support and Advocacy Service

Recruiting

Guanfacine Extended-release for Adolescents With Cannabis Use (GRACE)

Cannabis Use Disorder

Australia
Massachusetts General Hospital
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Active, not recruiting

Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

Chronic Pain

United States
Shire

Completed

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

Healthy

United States
Stanford University

Recruiting

The BIomarker Guided Study for Depression (BIG)

Major Depressive Disorder

United States
Yale University
National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaborators

Completed

Modeling Stress-precipitated Smoking Behavior for Medication Development

Smoking

United States
Icahn School of Medicine at Mount Sinai

Unknown

Guanfacine to Treat Borderline Personality Disorder

Borderline Personality Disorder

United States
Maimonides Medical Center

Recruiting

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome (PWS-GXR)

Aggression | Behavioral Symptoms | Pathologic Processes | Nervous System Diseases | Obesity | Neurologic Manifestations | Neurobehavioral Manifestations | Congenital Abnormalities | Overnutrition | Nutrition Disorders | Genetic Diseases, Inborn | Intellectual Disability | Self-Injurious Behavior | Abnormalities, Multiple and other conditions

United States
The University of Texas Health Science Center at...
Shire

Completed

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Active, not recruiting

A Trial of Guanfacine-er for Cannabis Use Disorder

Cannabis Use

United States
NYU Langone Health
Winthrop University Hospital

Withdrawn

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
UConn Health
Yale University; Shire

Withdrawn

Guanfacine Extended Release and Mindfulness Skills Therapy

Stress Disorder

United States
Research Foundation for Mental Hygiene, Inc.
Icahn School of Medicine at Mount Sinai; Bronx VA Medical Center

Unknown

Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia (Guanfacine)

Schizophrenia | Schizoaffective Disorder | Cognitive Impairment

United States
Yale University
University of South Florida; New York University; Icahn School of Medicine at... and other collaborators

Completed

Guanfacine in Children With Tic Disorders

Tourette Syndrome | Tourette Disorder

United States
New York State Psychiatric Institute
Shire

Completed

Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder

Oppositional Defiant Disorder | Attention Deficit Disorder | Childhood Aggression | Intermittent Explosive Disorder

United States
Lori A. Schweickert, MD
Shire

Completed

Inuniv and Working Memory

Attention Deficit Hyperactivity Disorder

United States
Janssen Research & Development, LLC

Completed

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Attention Deficit Disorder With Hyperactivity

United States
Shire

Completed

Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

Attention Deficit Hyperactivity Disorder (ADHD)

Spain, Germany, Ukraine, France, Italy, Austria, Belgium, Ireland, Netherlands, Poland, Romania, Sweden, United Kingdom
Yale University
National Institute of Mental Health (NIMH); Massachusetts General Hospital; University... and other collaborators

Completed

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

Pervasive Development Disorders

United States
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Recruiting

Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders

Alcohol Use

United States
Yale University
National Institute on Drug Abuse (NIDA)

Recruiting

Combining Varenicline and Guanfacine for Smoking Cessation

Smoking Cessation

United States
Shire

Completed

Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
JPM van Stralen Medicine Professional

Completed

Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD

Attention Deficit Hyperactivity Disorder

Canada
Norgine

Completed

Study to Examine the Efficacy and Safety of Movicol in the Treatment of Chronic Constipation in Children

Chronic Constipation

United Kingdom
Karolinska Institutet

Completed

ADHD Medication and Predictors of Treatment Outcome (ADAPT)

Attention Deficit Disorder With Hyperactivity (ADHD)

Sweden
National Institute of Mental Health (NIMH)

Completed

Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders

Autistic Disorder | Attention Deficit Disorder With Hyperactivity | Pervasive Development Disorders

United States
McGill University Health Centre/Research Institute...

Unknown

The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

Canada
Imperial College London

Recruiting

Noradrenergic Add-on Therapy With Guanfacine (NorAD)

Alzheimer Disease

United Kingdom
Vanderbilt University Medical Center
Massachusetts General Hospital; National Institute on Aging (NIA)

Active, not recruiting

Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study (MENDING)

Delirium | Critical Illness | Cognitive Impairment

United States
Vanderbilt University Medical Center

Completed

Guanfacine for PONV and Pain After Sinus Surgery

Pain, Postoperative | Postoperative Nausea and Vomiting

United States

Search clinical trials for: Guanfacine Hydrocholride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations